New Recruiting Trial: Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
WHY IT MATTERS
This trial offers a new treatment option for patients with relapsed or refractory AML, a condition with limited effective therapies, and is actively recruiting participants now.
Researchers are testing a new combination of three drugs—bugitinib, venetoclax, and cytarabine—to treat acute myeloid leukemia (AML) that has come back or stopped responding to previous treatment. This is an early-stage study (Phase 2) that is now accepting patients. The goal is to see if this drug combination works better than current options for this serious blood cancer.
NCT ID: NCT07563179 Title: Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia Status: RECRUITING Phase: PHASE2 Sponsor: Shenzhen University General Hospital Start date: 2026-04-21 URL: https://clinicaltrials.gov/study/NCT07563179 Source: UniteRare clinical trials database
YOU CAN ACT ON THIS
If you or a loved one has relapsed or refractory AML, ask your oncologist whether you might be eligible for this trial—enrollment is open and the study begins in April 2026.